The sample for patient 3 was submitted for investigation.Further investigation of the sample suggests an interfering factor against the streptavidin component of the reagent is present.Product labeling states: "in rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.These effects are minimized by suitable test design." the investigation is ongoing.
|
The sample for patient 3 was investigated further.The follow up report stated: "further investigation of the sample suggests an interfering factor against the streptavidin component of the reagent is present." this should say: "further investigation of the sample suggests an interfering factor against the component of the reagent is present.The specific interference could not be determined, however, it is consistent with an antibody interference." product labeling states: "in rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.These effects are minimized by suitable test design.For diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination and other findings." this interference caused the high ft3 iii and ft4 iii results for sample 3.Samples 1 and 2 were not available for investigation.The investigation did not identify a product problem.
|